Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event
15 Marzo 2023 - 7:30AM
Business Wire
Regulatory News:
POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a
clinical stage biopharmaceutical company developing innovative
treatments for serious chronic diseases with metabolic
pathophysiology, including non-alcoholic steatohepatitis (NASH) and
rare metabolic disorders, today announced its participation at the
NASH Renaissance virtual event hosted by Evercore ISI on Thursday,
March 30, 2023.
The Company will present the positive results from the Phase 2
NASH trial (DESTINY-1) for PXL065, a novel, proprietary
deuterium-stabilized R-stereoisomer of pioglitazone which has
reduced PPARγ activity, but retains non-genomic pioglitazone
actions.
Members of the Poxel management team will be available for
virtual one-on-one meetings with investors on Friday, March 31,
2023.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. For the treatment of
NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its
primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is focused on the treatment of adrenoleukodystrophy
(ALD) and autosomal dominant polycystic kidney disease (ADPKD).
TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is marketed for the treatment of
type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to
receive royalties and sales-based payments. Poxel has a strategic
partnership with Sumitomo Pharma for Imeglimin in Japan, China, and
eleven other Asian countries. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements. The Company does not endorse or is
not otherwise responsible for the content of external hyperlinks
referred to in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230314005950/en/
Investor relations / Media Aurélie Bozza Investor
Relations & Communication Senior Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36 Elizabeth Woo
Senior Vice President, Investor Relations & Communication
elizabeth.woo@poxelpharma.com NewCap Emmanuel Huynh or Arthur
Rouillé poxel@newcap.eu +33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Apr 2023 a Apr 2024